PMID- 37307732
OWN - NLM
STAT- MEDLINE
DCOM- 20230622
LR  - 20230622
IS  - 1873-3336 (Electronic)
IS  - 0304-3894 (Linking)
VI  - 457
DP  - 2023 Sep 5
TI  - Mitigation of maternal fecal microbiota transplantation on neurobehavioral 
      deficits of offspring rats prenatally exposed to arsenic: Role of 
      microbiota-gut-brain axis.
PG  - 131816
LID - S0304-3894(23)01099-3 [pii]
LID - 10.1016/j.jhazmat.2023.131816 [doi]
AB  - It is established that gut microbiota dysbiosis is implicated in arsenic 
      (As)-induced neurotoxic process, however, the underlying mode of action remains 
      largely unclear. Here, through remodeling gut microbiota on As-intoxicated 
      pregnancy rats using fecal microbiota transplantation (FMT) from Control rats, 
      neuronal loss and neurobehavioral deficits in offspring prenatally exposed to As 
      were significantly alleviated after maternal FMT treatment. In prenatal 
      As-challenged offspring after maternal FMT treatment, remarkably, suppressed 
      expression of inflammatory cytokines in tissues (colon, serum, and striatum) were 
      observed along with reversed mRNA and protein expression of tight junction 
      related molecules in intestinal barrier and blood-brain barrier (BBB); Further, 
      expression of serum lipopolysaccharide (LPS), toll-like receptor 4 (TLR4), 
      myeloid differentiation factor 88 (Myd88) and nuclear transcription factor-kappaB 
      (NF-kappaB) in colonic and striatal tissues were repressed with activation of 
      astrocytes and microglia inhibited. In particular, tightly correlated and 
      enriched microbiomes were identified such as higher-expressed g_Prevotella, 
      g_UCG_005, and lower-expressed p_Desulfobacterota, 
      g_Eubacterium_xylanophilum_group. Collectively, our results first demonstrated 
      that reconstruction of normal gut microbiota by maternal FMT treatment alleviated 
      prenatal As-induced overall inflammatory state and impairments of intestinal 
      barrier and BBB integrity by impeding LPS-mediated TLR4/Myd88/NF-kappaB signaling 
      pathway through microbiota-gut-brain axis, which provides a novel therapeutic 
      avenue for developmental arsenic neurotoxicity.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Zhao, Qian
AU  - Zhao Q
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Hao, Yan
AU  - Hao Y
AD  - Center for Disease Control and Prevention of Daxing District, Beijing, China.
FAU - Yang, Xiaoqian
AU  - Yang X
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Mao, Jie
AU  - Mao J
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Tian, Fengjie
AU  - Tian F
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Gao, Yi
AU  - Gao Y
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Tian, Xiaolin
AU  - Tian X
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Yan, Xiaoyan
AU  - Yan X
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Qiu, Yulan
AU  - Qiu Y
AD  - School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China. 
      Electronic address: ylqiu@sxmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230608
PL  - Netherlands
TA  - J Hazard Mater
JT  - Journal of hazardous materials
JID - 9422688
RN  - 0 (Toll-Like Receptor 4)
RN  - N712M78A8G (Arsenic)
RN  - 0 (NF-kappa B)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Myeloid Differentiation Factor 88)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Pregnancy
MH  - Female
MH  - *Fecal Microbiota Transplantation
MH  - Toll-Like Receptor 4/genetics/metabolism
MH  - Brain-Gut Axis
MH  - *Arsenic/toxicity/metabolism
MH  - NF-kappa B/metabolism
MH  - Lipopolysaccharides/toxicity
MH  - Myeloid Differentiation Factor 88/metabolism
OTO - NOTNLM
OT  - Maternal FMT treatment
OT  - Microbiota-gut-brain axis
OT  - Neurobehavioral deficits
OT  - Prenatal arsenic exposure
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/12 19:12
MHDA- 2023/06/22 06:42
CRDT- 2023/06/12 18:06
PHST- 2023/03/21 00:00 [received]
PHST- 2023/05/26 00:00 [revised]
PHST- 2023/06/07 00:00 [accepted]
PHST- 2023/06/22 06:42 [medline]
PHST- 2023/06/12 19:12 [pubmed]
PHST- 2023/06/12 18:06 [entrez]
AID - S0304-3894(23)01099-3 [pii]
AID - 10.1016/j.jhazmat.2023.131816 [doi]
PST - ppublish
SO  - J Hazard Mater. 2023 Sep 5;457:131816. doi: 10.1016/j.jhazmat.2023.131816. Epub 
      2023 Jun 8.